Post by Explicyte

#Oncology #Targets Our 2025 Database of Anti-#B7H3 / #B7H4 Therapeutic Programmes in oncology is available for download https://lnkd.in/dfvkJEQM 🔬 What’s inside? ✅ 17 Antibody-drug conjugate (ADC) programmes ✅ 11 Bispecifics & 2 monoclonal antibodies (mAbs) targeting B7-H3 or B7-H4 ✅  6 CART-T & CAR-NK programmes ✅ 1 radiotherapy (RT) programme (Phase II) based on an anti-B7-H3 mAb Featuring anti-B7-H3/B7-H4 programmes from leading players, including: ABL Bio Inc., Amgen, Anhui Anke Biotechnology (Group) Co., Ltd., AstraZeneca, BioNTech SE, Bio-Thera Solutions, Biocytogen, Cullinan Oncology, Daiichi Sankyo US, Dartsbio Pharmaceutical Co., Ltd., Duality Biologics, Five Prime, GSK, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Harbour BioMed, Iksuda Therapeutics, 리가켐 바이오사이언스 Ligachembio Sciences, Mabstone Biotechnologies, MacroGenics, Inc., Maverick Therapeutics, MediLink Therapeutics, Memorial Sloan Kettering Cancer Center, Merck, Mersana Therapeutics, Shanghai Minghui Pharmaceutical, NextCure, Inc., Pfizer, Seagen, Synaffix, Lonza, Takeda, Xencor, Y-mAbs Therapeutics, Inc.- and more! Explicyte Immuno-Oncology